Can Synthetic Biology Finally Cure Diabetes? – Slate Magazine
Slate Magazine |
Can Synthetic Biology Finally Cure Diabetes?
Slate Magazine More recently, though, the field of synthetic biology—a hybrid discipline that aims to construct or redesign biological components and systems—has shown the potential to produce a novel set of treatments. The solutions remain speculative, but they do … |
|
Using CRISPR against cancer shows success in mice – Futurity
Futurity: Research News Using CRISPR to edit the “fusion genes” that can cause or worsen cancer reduced the size of tumors and improved survival in mice, report researchers. |
Cosmos |
How ‘smart’ stem cells could lead to arthritis vaccine
Futurity: Research News Researchers have modified mouse stem cells to combat the kind of inflammation that arthritis and other conditions cause. The stem cells may one day be used in a vaccine that would fight arthritis and other chronic inflammation conditions in humans, a … SMART cells to fight arthritisCosmos Gene editing could lead to a vaccine for arthritisEngadget |
Reuters |
AstraZeneca immunotherapy wins first approval in bladder cancer
Reuters U.S. regulators have approved AstraZeneca’s key immunotherapy drug durvalumab as a treatment for bladder cancer, marking the first commercial green light for a product the company hopes will go on to sell billions of dollars. The approval, while … AstraZeneca gains FDA approval for durvalumabBioPharma Dive |
Reuters |
FDA approves AstraZeneca’s immunotherapy for bladder cancer
Reuters FDA approves AstraZeneca’s immunotherapy for bladder cancer. FILE PHOTO: The logo of AstraZeneca is seen on a medication package at a pharmacy in London April 28, 2014. REUTERS/Stefan Wermuth/File Photo. The U.S. Food and Drug Administration … |
|
U.S. FDA approves AstraZeneca’s immunotherapy for bladder cancer
Yahoo Finance May 1 (Reuters) – The U.S. Food and Drug Administration on Monday granted accelerated approval to AstraZeneca Plc’s immuno-oncology drug to treat a type of bladder cancer in patients whose disease progressed despite chemotherapy. The drug, called … |